Health Condition 1: C348- Malignant neoplasm of overlappingsites of bronchus and lung
Conditions
Interventions
Intervention1: pharmacist intervention for NGS testing group: patients are assigned into two groups NGS uptaking group and non NGS taking group where one group is undergoing pharmacist intervention an
Sponsors
KLE Academy of Higher Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: Patients with age above Eighteen years at the time of therapy Patients with confirmed non-small cell lung cancer based on pathological or histological analysis. Patients who have undergone NGS testing to identify actionable mutations Patients receiving targeted therapies or other treatments guided by NGS results
Exclusion criteria
Exclusion criteria: Patients with other types of lung cancer apart from non-small cell lung cancer Patients receiving anti-cancer treatment not governed by Next generation sequencing testing Patients with incomplete genetic profiling or inadequate follow-up data Patients who refuse to provide consent or are not cooperative Pregnant women and lactating mothers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Individual mutational variants. Optimal drug therapies. Patient-reported outcomesTimepoint: Baseline Baseline three months six months twelve months and eighteen months | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug related problems through pharmacist led intervention & patient counseling Pharmacoeconomic dataTimepoint: Three months six months twelve months & eighteen months | — |
Countries
India
Contacts
Public ContactDr S Spurthi
KLE University
Outcome results
None listed